Clinical Trials and Research: Hemophilia and Thrombosis Treatment Center

Our patients can participate in cutting-edge research through a variety of clinical trials. The trials are multi-center trials, carried out in a number of centers throughout the United States and around the world. Your participation helps by:

• Furthering our understanding of morbidities such as joint disease and cardiovascular disease in adult patients with hemophilia
• Allowing us to study new treatment options to improve future care.

There is no cost for the studies or clotting factor preparations, and you are reimbursed for time, effort, and travel costs. To learn more, call the Hemophilia Treatment Center, 619-471-0335, Monday to Friday, 8:30 a.m. – 4:30 p.m. 

Available trials

For patients with severe Hemophilia A 

• Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A
  Study Sponsor: Biogen-Idec Hemophilia

For patients with severe or moderately severe Hemophilia B

• Pivotal Study (Pharmacokinetics (PK), Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B
  Study Sponsor: Baxter Healthcare Corporation 

For patients with severe Hemophilia A or B

• Bone and Joint Health in an Adult Hemophilia Population
  Study Sponsor: Baxter Healthcare Corporation